Aktis Oncology FDA Clearance of Investigational New Drug Applications for AKY-2519

 

• Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populations
• Anticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in mid-2026

https://www.globenewswire.com/news-release/2026/03/30/3264994/0/en/Aktis-Oncology-Announces-FDA-Clearance-of-Investigational-New-Drug-Applications-for-AKY-2519-and-Provides-Business-Updates-and-Full-Year-2025-Financial-Results.html